Vincentage Pharma touts Phase III win for oral GLP-1RA

While Vincentage's study will only support approval of the oral GLP-1RA in China, the drug is in a Phase II trial in the US. While Vincentage's study will only support approval of the oral GLP-1RA in China, the drug is in a Phase II trial in the US. The oral GLP-1RA showed benefit in a Phase III trial in China. Credit: Artem Stepanov / Shutterstock.com China-based Vincentage Pharma is hot on Eli Lilly and Novo Nordisk’s heels after its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) met its endpoints in a Phase III obesity trial. At 52 weeks, VCT220 achieved mean…

Source: Clinical Trials Arena